tirzepatide shortage fda update says the weight-loss drug is over Zepbound, Mounjaro shortages are resolved,

Investor Takeaway For investors seeking exposure to the GLP-1 boom in India, the key is to identify companies with proven capabilities in: Peptide synthesis Sterile injectable manufacturing Global regulatory compliance CDMO services with US/EU clients Recommended Monitoring: R&D updates and capacity expansions Any tie-ups with global GLP-1 players Clinical trial progress for biosimilar versions Regulatory approvals (USFDA, EMA) Export data to key markets (USA, Canada, China) Conclusion The weight loss drug boom is changing global healthcare and creating a huge business opportunity for Indian pharma companies

Furthermore, no convincing evidence currently supports a direct association between gut microbiota composition and the risk of GLP-1 receptor agonist-associated pancreatitis

The majority of people who start them dont stop taking them

Sleep plays a pivotal role in forming healthy habits

Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases